DNAPrint Genomics last week said it has appointed Karen Surplus as its chief financial officer, effective immediately, to replace Monica Tamborini, who is retiring.
Surplus is a certified public accountant, and operated her own financial consulting business for the past three years. Previously, she served as CFO of Digital Fusion from 1999 to 2003, and was chief accounting officer at PowerCerv from 1995 to 1999. She earned an MBA from the University of Tampa in May 1992.
Solexa this week appointed Richard Lussier to the newly created position of vice president of sales and field operations, the company said. Lussier will be responsible for hiring and managing a field sales staff supporting the Solexa Genome Analysis System. Lussier was president and general manager of Applied Biosystems Japan for five of his 12 years at ABI.
He also managed the Asia-Pacific operations for Celera Genomics and held global field operations management positions with MJ Research and Fluidigm, where he was senior vice president of field operations, Solexa said. Lussier holds an MBA from Temple University and conducted post-graduate studies in molecular biology at the University of Vermont.
Tony Marchington joined Genome Explorations as its chief operating officer, the company said last week.
Marchington established Oxford Molecular in 1989, the first spin-out from Isis Innovation, an intellectual property company for Oxford University. The company became part of Millenium Pharmaceuticals in 2000. Prior to Oxford Molecular, he worked for ICI, now AstraZeneca, in discovery medicinal chemistry.
Marchington received both his MA and doctorate degrees in chemistry from Oxford.
He is an adviser to the UK Government as a member of the Department of Trade and Industry's Competitiveness Advisory Group, and a member of the Pharmaceuticals Panel of the UK DTI Foresight Initiative.
DeCode Genetics appointed Birgit Norinder to its board of directors, the company said last week. The appointment is effective immediately.
Norinder held senior clinical development and regulatory affairs positions in Europe and US at Pfizer, Astra, Glaxo, and Pharmacia & Upjohn. She was CEO and chairman of UK-based Prolifix until its merger with TopoTarget in 2002.
She currently serves on the boards of Antisoma, Artimplant, Photocure, and Biolipox. She is chairman of the board for Betagenon.